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SHORT INTRODUCTION 
The overarching purpose of this thesis is to investigate the expression of human genes 
and how they relate to cardiovascular disease. Consequently, the ultimate goal is to 
benefit the patients who are suffering from cardiovascular disease.  The only way to 
improve our treatment of disease is by advancing our knowledge about it. Already, this 
knowledge is vast and expanding and the work presented herein is therefore only a 
small piece of a very large context of research, all aimed at this same goal. 
The context is that of the medical and biological science of 2011, at a time when a 
genomic era of medicine has already been declared several times, but where the actual 
impact of genomics on medicine is lacking. It is a time when headlines routinely report 
the identification of the genes for one disease or another, but where it is harder to 
suggest direct practical uses for these new findings. One suggestion that is hard to 
dispute, however, is that the findings increase our knowledge of disease and that we 
should strive to translate them into clinical application. Translational medical research 
is the catchphrase applied to this suggestion.  
Since the discovery of the genomic code in the 1960s, it has been known that biological 
information flows from the genome into practical form and function as proteins. Gene 
expression is the intermediate of this path and any genomic concept is likely to be 
mediated through transcription in one way or another. And so, taking cue from the cell 
itself, the proper subject for translating genomic era findings to the clinical application 
is to study the products of the genes. 
The pieces of the puzzle provided by this thesis all concern gene expression and they 
all concern translation into medical application. Each of the five papers included 
investigate different aspects of this focus point. One paper investigates the technology 
for extracting gene expression information (I). Two look from the genome towards the 
gene expression in order to interpret genomics better (II and III).  Another paper looks 
from disease towards gene expression to seek clues on the mechanism of disease (IV). 
And finally the last paper observes the gene expression, irrespective of its biological 
meaning, and asks how much it can tell about the future of a patient (V). 
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1 BACKGROUND 
1.1 GENOMICS 
DNA is the means by which the design for an organism is stored. It is the means by 
which an organism conveys itself to future generations. Because of the impact of this 
design on the future generations, it is the fabric on which the evolution of life is taking 
place. 
A sequence of 3.2 billion DNA nucleotides constitutes the genome of humans. 
However, the nucleotide composition is not exactly the same for all humans – there are 
variations such as the single-nucleotide polymorphisms (SNPs) as well as larger 
segments of re-arrangements of the DNA sequence. These sequence variations are 
observed even between siblings. The similarities become fewer and the differences 
increase as comparison is made between more distantly related humans. For example, 
the Neanderthals, our now extinct relatives, show similarities with some modern human 
ethnicities of up to 99.99% identity (Green et al. 2010). In chimpanzees this number is 
99.0% (Mikkelsen et al. 2005). This pattern is continued, with steadily decreasing 
similarity between humans and other organisms; e.g. mice (~40%) (Waterston et al. 
2002) and dogs (~32%) (Lindblad-Toh et al. 2005). It continues throughout the tree of 
life, to plants and bacteria where little sequence is identical. 
Clearly, DNA sequence variations have the ability to effect large alterations in form 
and function of any organism. Yet, only the more extreme cases of genetic variation 
have appreciable and plainly observed effects on the medical futures of individual 
humans. The idea that more medically relevant information can be extracted from an 
individual’s DNA motivates modern genetics research which seeks to explain the less 
plainly observed effects of genetic variation. 
Recent milestones towards this goal includes the completion of the human genome 
sequence (Lander et al. 2001), the identification of common human sequence variation 
(HapMap 2003), and the development of efficient methods to measure this variation 
(Schena et al. 1995). Taken together, these advances allowed the genome wide 
association study (GWAS) (Klein et al. 2005). In this first study 96 individuals with 
age-related macular degeneration were compared with 50 healthy control subjects and 
two SNPs that had a significant association with disease were reported.  
Today, thousands of GWAS papers have been published and even more SNPs have 
been associated with a vast range of diseases. In spite of all the statistical complexity 
found in these GWAS papers, the basic methodology is unaltered from 2005 and 
distinctly simple; a group of individuals with a trait of interest is compared to a group 
of people without this trait. If there are one or more SNPs that have significantly 
different frequencies between the two groups they are said to be associated. For 
example it is an association when 2000 individuals with a cardiovascular disease have a 
SNP with C-allele frequency of 47.4%, but its C-allele frequency is 55.4% in 3000 
healthy individuals. This example was in fact the case for the first SNP reported for 
cardiovascular disease, e.g. (The Wellcome Trust Case Control Consortium 2007), 
which have since been widely replicated. 
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Since the earliest GWAS, there have been two major trends in study setups. One has 
been towards larger sample sizes (C4D 2011; Schunkert et al. 2011) and one has been 
towards a wider selection of intermediate phenotypes, e.g. (Kathiresan et al. 2009a; 
Strawbridge et al. 2011).  Larger sample sizes allow the discovery of smaller effects in 
high-variation data affected by many known and unknown co-variates. Intermediate 
phenotypes, allow the decrease of this variation because of focus on discrete 
pathophysiological pathways. It is outside the scope of this thesis to report all 
cardiovascular GWAS findings, but more detailed accounts are provided elsewhere, 
e.g. (Malarstig et al. 2010).  
Even with thousands of discovered associated variants, their application towards 
directly improving human health is sparse. It is often stated that the variability in 
disease patterns explained by known risk-SNPs is too small to have substantial effect 
on clinical decision. This point, however, is fiercely debated. An important notion that 
sidesteps the debate is that GWAS results also provide access to greater understanding 
of the pathophysiology itself. The reason is the strong ability to show causality in 
humans. Usually, association does not guarantee causation. However, in GWAS setups 
the far most plausible explanation for association is that the altered SNP-frequency 
causes the altered disease-risk. The opposite direction would make little biological 
sense and it is difficult to envision non-genetic confounding effects. Hence, a large part 
of the popularity of GWAS comes from the fact that they allow the discovery of 
causative links to disease in humans.  
 
 
1.2 TRANSCRIPTOMICS 
Upon transcription of DNA, RNA is created. Often the future fate of an RNA molecule 
is translation into protein – other times it has direct RNA-based functions. In all cases, 
however, RNA is the first step in realizing the information content of the genome. For 
this reason it is of much interest to characterize and quantify the flow of mRNA, and 
this field is called transcriptomics. 
As with the DNA that it reflects, the sequence of mRNA can vary between individuals 
(Li et al. 2011). In addition, however, there are much more important variations in the 
quantity and splicing of mRNA. Unlike DNA, these variations are different between 
different cells of the body and between different times and states of these cells. Perhaps 
as a result of this complexity, the analysis and characterization of RNA is much less 
clear-cut than that of DNA. On the other hand, one can argue that this makes RNA and 
gene expression analysis more relevant and well-timed for any given medical question. 
For this reason, a multitude of studies have investigated transcriptomics as a means to 
unravel the molecular background of disease. Typically, expression profiles of 
circulating cells was compared between patients and healthy individuals (Chon et al. 
2004), or tissue biopsies was used to compare different forms of a disease (Barth et al. 
2005; Barth et al. 2006; Majumdar et al. 2007; Phillippi et al. 2009). This type of 
comparative expression profiling studies has highlighted several potential target genes, 
but unlike the GWAS approach there is little assessment of the differences between 
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cause and effect. A gene with up-regulated expression in disease could just as well be a 
response to disease as it could be a cause of disease. 
Perhaps because of this, many studies are being reconsidered in ways that more clearly 
separate causes and effects. As discussed later in the Paper III section, studies of the 
link between risk-SNPs and expression are one way of strengthening the argument for 
triggering roles in disease. Another attempt to separate cause and effect is central in the 
discussion of Paper IV. 
 
1.3 DISEASE 
The medical scope of this thesis is cardiovascular disease from several angles. Paper II 
is based on the results of GWAS investigating myocardial infarction, but Paper III 
includes both this endpoint and several other risk factors – from lipid levels to blood 
pressure measurements. Paper IV focuses specifically on thoracic aortic aneurysm, and 
is thus the most disease specific work. Paper V is based on predicting future ischemic 
strokes and myocardial infarctions.  
1.3.1 Myocardial infarctions, ischemic strokes and their causes 
Two common and sometimes fatal medical events are myocardial infarction and 
ischemic stroke. Both are results of blockage, or occlusion, of important vessels. In the 
case of myocardial infarction, it is occlusion of the coronary arteries of the heart, and in 
the case of ischemic stroke, it is the vessels of the brain. In the vast majority of cases, 
this occlusion is a result of the rupture of a vulnerable atherosclerotic plaque, creating a 
detached mass, an embolus, which eventually will cause the occlusion. Therefore 
atherosclerosis is a main cause of both myocardial infarction and ischemic stroke. 
Unfortunately, the straightforward description of causality ends at this point. The 
causes and risk-factors for atherosclerotic plaques are many, and instability and 
tendency to form emboli, rather than just existence and size of the plaque, are thought 
to have profound influence on the risk of future adverse events.  
Low-density lipoprotein (LDL) is well established to play a role in the atherosclerosis 
(Goldstein et al. 1974; Ridker et al. 2008; Goldstein et al. 2009). Treatment with statins, 
which lowers LDL, prevents cardiovascular events in survivors of a first-time 
myocardial infarction (Pedersen et al. 1994) and in subjects with high cardiovascular 
risk (Shepherd et al. 1995). Likewise, it is well established that conditions such as high 
blood pressure and diabetes are strongly associated with increased risk of myocardial 
infarction and ischemic strokes. Other commonly used biomarkers such as serum C-
reactive protein (CRP) and serum high-density lipoprotein (HDL), are correlated to 
atherosclerosis (inversely in the case of HDL), but their actual causal roles are more 
controversial (Danesh et al. 2009; Nordestgaard et al. 2011).  
Taken together, and adding a multitude of other real and suspected risk factors, it is 
indeed fair to characterize myocardial infarction and ischemic stroke as a complex 
multi-factorial diseases. For the purposes of this thesis a key point is as follows: in 
addition to the risk factors we know are causal and the ones we think might be causal, 
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there are plenty of potentially completely unknown factors. Knowledge of these could 
both be immensely helpful in diagnosis as well as in treatment of complex 
cardiovascular disease. 
1.3.2 Thoracic aortic aneurysm and bicuspid aortic valve 
Paper IV focuses on thoracic aortic aneurysm (TAA). As with myocardial infarction 
and ischemic stroke, TAA is potentially fatal. Fatality from TAA happens when the 
aorta is dilated to the point where the vessel wall is broken, either as a rupture or as a 
dissection of the aorta. One important clinical observation is that amongst TAA patients 
there is an increased prevalence of patients with bicuspid aortic valve (BAV). This 
observation is still unexplained, and underlies the main question asked in Paper IV. The 
aortic valve is the heart valve that controls flow out of the left ventricle and normally it 
has three cusps (tricuspid aortic valve, or TAV).  BAV is a common congenital 
cardiovascular malformation with prevalence of 1-2%, in which two cusps of the aortic 
valve are fused together (Figure 1). The aneurysms of patients with BAV grow faster 
and their TAA develop at a younger age than patients with TAV (Nkomo et al. 2003; 
El-Hamamsy et al. 2009; Jackson et al. 2011b).  
 
TAA and BAV are thought to have strong heritable components (Cripe et al. 2004; Siu 
et al. 2010). However, no specific causative mutations have been identified. Suggested 
candidate genes include the NOTCH1, ACTA2, FBN1 and the genes encoding the 
collagens, elastin, matrix-metalloproteinases and TGF-β (El-Hamamsy et al. 2009; Siu 
et al. 2010). In addition, it was recently observed in a GWAS that SNPs in the FBN1 
gene were associated with TAA and aortic dissection (Lemaire et al. 2011). In further 
support of these candidate genes, it is of interest to mention the few rare syndromic 
forms of TAA because they involve known causal genes. These are the Marfan 
syndrome involving FBN1 (Ramirez et al. 2007) and the Loeys-Dietz syndrome 
involving the TGF-β receptors (Loeys et al. 2006).  
An important point of discussion on the pathophysiology of BAV is the question of 
hemodynamic changes caused by the malformed aortic valve. Studies have shown that 
BAV patients have perturbed aortic flow and it is hypothesized that this disturbance 
could result in the disease development (Hope et al. 2010). An alternative hypothesis, 
however, is that the same genetic factors which cause BAV also lead to increased TAA 
risk. This is supported by the fact that the TAA risk in BAV patients is unaffected after 
aortic valve replacement (Yasuda et al. 2003). As further discussed in the Paper IV 
section, this controversy is still subject to discussion. 
Figure 1. Illustration of a 
normal tricuspid aortic 
valve (left) and a bicuspid 
aortic valve, with fusion of 
the right- and left coronary 
cusp (right). 
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2 METHODS  
2.1 GENETICS 
Common methods to characterize DNA variation range all the way from the Sanger 
dideoxy-method, which was the next generation sequencing of 1977 (Sanger et al. 
1977), to the latest high-throughput technologies based on massively parallel 
sequencing. A fundamental point of methodology is to distinguish the aim of 
determining all sequence and its variation in a given DNA sample (sequencing), with 
the aim of observing specific known variations in a DNA sample (genotyping). The 
latter aim can be accomplished with genotype specific PCR amplification for individual 
SNPs or genotyping microarrays which covers all common SNPs in the human 
genome. Because GWAS almost exclusively are based on data from genotyping 
microarrays, the work in this thesis is designed around this method. 
2.1.1 Quality metrics 
The vast majority of genotyping measurements referred to in this thesis were performed 
using Illumina Human 610W-Quad Beadarrays at the SNP technology platform at 
Uppsala University. Part of the quality control was done at the core centre, where SNP-
calling and SNP exclusion based on standard Illumina metrics were performed. In 
addition to core-center methodology, we performed three quality control tests. Firstly, 
duplicate samples were submitted for three patients. This showed a genotyping 
concordance rate of 99.90%. Secondly, 8 SNPs had previously been genotyped with a 
taqman PCR-based method in 89 samples from the BiKE cohort. These showed only 1 
Figure 2. Principal 
components analysis (PCA) of 
ASAP genotype data based on 
self-reported place of birth. 
The principal components on 
each axis do not have any 
direct biological corollary, but 
the purpose of the PCA here is 
to cluster samples with similar 
genotypes together. Both 
principal components have 
been square-root transformed 
for a better view of relevant 
clustering. 
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discrepant genotype, corresponding to a concordance rate of 99.86%. Thirdly, we 
investigated sample switching frequency by comparing gender and place-of-birth 
information with genotypes. All samples with Y-chromosome genotype calls were 
registered as male and vice versa for females. Principal components analysis of all 
genotypes combined with labelling by birth place (Figure 2) showed strong clustering 
of nationalities as expected (Novembre et al. 2008). 
2.1.2 Imputation 
In addition to the directly genotyped SNPs, several cases required knowledge of SNPs 
which were not directly measured. This data was obtained through imputation. 
Imputation is the process of estimating the genotypes of SNPs that are not measured, 
based on information from proximal SNPs that have been measured and information on 
linkage disequilibrium as obtained from either the HapMap consortia (HapMap 2003) 
or the 1000 genomes project (Durbin et al. 2010). Essentially the process allows 
guessing an additional 4-5 million SNPs from the measurement of only half a million. 
Imputations in this thesis have been performed either with the Plink algorithm (Purcell 
et al. 2003) or the Mach 1.0 algorithm (Li et al. 2010), based on HapMap reference data 
or 1000 genomes data, respectively. All imputation calculations were performed on the 
UPPMAX computing cluster. 
2.2 TRANSCRIPTOMICS 
Several methods exist to quantify the amount of mRNA in a sample – starting from the 
very first northern blots, over real-time PCR, gene-expression microarrays and into 
high throughput RNA sequencing. All these methods have differences, strengths and 
shortcomings, but the general trend has been to move towards higher throughput (more 
genes measured at the same time), and higher resolution (more complete knowledge of 
RNA transcript architecture). While there can be no doubt that throughput and 
resolution is improving, previous methods still have their proponents in terms of 
precision, accuracy and price-considerations and most published gene expression 
studies are required to undergo validation using real-time PCR.  
2.2.1 Quality metrics 
A later section in the statistics section is dedicated to a discussion of terms in 
validation, but for a general introduction to gene expression measurement it is of 
interest to establish if the different methods show the same results. Expression 
microarrays and real-time PCR were compared in a study by the MicroArray Quality 
Control consortium, which tested a broad range of platforms and different test sites in a 
small collection of standardized samples (Canales et al. 2006; Shi et al. 2006). The type 
of expression microarray also used in the BiKE cohort, was reported to give a 
correlation of R = 0.92 over ~450 genes when comparing fold-changes between two 
samples. Of interest, a later study found a correlation of R = 0.95, between real-time 
PCR and high-throughput sequencing in the same samples (Wang et al. 2008). 
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A more relevant quality metric to the works presented here would be how individual 
gene expression levels compare across samples, when using different measurement 
methods. The reason is that virtually no comparisons are made between the expression 
levels of different genes. Most comparisons are of individual genes and their expression 
level between different sample types, e.g. in different genotypes or in different patient 
groups. Of interest to this type of question is a study, comparing 53 cell line samples 
for which gene expression was available both from a high-throughput RNA-sequencing 
platform and from expression microarrays (Pickrell et al. 2010). Correlations in the 
range 0.60 to 0.78 was observed across genes, but across samples this dropped to an 
average of 0.3 (range -0.4 – 0.9), for all genes at the medium-high expression level. 
Correlation was worse at more extreme expression levels. Cross-sample studies 
between expression microarray and real-time PCR data in the BiKE database showed 
an average correlation of 0.53 (range 0.17 – 0.76) in 15 genes over 88 samples 
(Folkersen et al. 2009b). Compared to correlations across genes, these across-sample 
correlations are disappointing, and the high level of variance is worth keeping in mind 
when interpreting transcriptomics data here and in general. 
2.2.2 Array mechanism and design 
Several different companies manufacture expression microarrays. Common for all is a 
mechanism based on hybridisation of a sample of unknown labelled RNA sequences 
(the sample), to a set of known short RNA sequences located in an array with defined 
positions (the probes). After hybridization, a scan of the array will reveal the amount of 
labelled unknown RNA at each position, which can then be translated to a quantitative 
parameter for the RNA at that particular position. Before hybridization, a number of 
reverse transcriptions, amplification, or fragmentation steps might be performed, but 
this depends on the brand and type of expression microarray. Likewise there are 
differences in the organization of probes, where some companies use one or two longer 
probes for each gene (Agilent, Illumina) and others group several shorter probes for the 
same gene or gene region into so-called probe sets (Affymetrix). 
Gene 
Transcript 1 
Agilent / spotted arrays / others
Probe 2 Probe 3 
Transcript 2 
HG-U133 plus 2.0 
Probe set 1 Probe set 2 
Probe 1 
Probe set 1 Probe set 2 Probe set 3 Probe set 4 
Affymetrix ST 1.0 exon 
Meta probe set 
Figure 3. Overview of concepts in the organization of Affymetrix expression arrays. 
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Particularly for Paper I and II, it is important to explain the organization of these probe 
sets on Affymetrix expression microarrays in detail. Unfortunately some of the terms 
can be confusing as their meaning change with the type of Affymetrix microarray. In 
all cases the term probe is defined as meaning a 25 nucleotide long sequence, designed 
to match in one, and only one, region of a gene. Groups of 4-13 of these probes are 
termed as probe sets and the probes from a set always match genomic locations in close 
proximity to each other. In the older generation of expression microarrays, of which the 
HG-U133 plus 2.0 is part, these probe sets are focused at the 3’ part of the gene, and 
their hybridization intensity is meant to be taken as a value for the quantity of the entire 
gene. In the newer generation of expression microarrays, of which the ST 1.0 exon 
array is part, these probe sets are distributed over the gene, with approximately one 
probe set per exon. In this array type, the probe set value is meant to be taken as the 
quantity of an individual exon. The value of an entire gene, is then retrieved from 
grouping all probes, from all gene-specific probe sets into one so-called meta probe set, 
which is meant to be taken as the quantity of the entire gene. This organization is 
illustrated in Figure 3. The main point to keep in mind is that different array types 
organize their probes differently – either they all can be summarized to yield one value 
for one gene, or else one can keep track of individual probes in order to reveal more 
detailed information. 
2.2.3 Normalization and pre-processing 
The last point of microarray analysis is how to arrive at one value per gene and per 
sample which is comparable across the study. Because of the fragmentation, 
amplification and hybridization steps, there will be systematic hybridization intensity 
variation between any two arrays. A normalization step is therefore required. Also, 
because of the organization of probes described above, a step of summarization must be 
included. Often some kind of background estimation and subtraction is included as 
well. These matters of pre-processing can be the source of much discussion and many 
competing algorithms have been developed. These have been fully reviewed elsewhere 
(Calza et al. 2010). Today, PLIER and RMA seem to be generally accepted norms for 
pre-processing, even though both include some rather drastic assumptions which might 
not hold when comparing samples with large differences. In support of RMA and 
PLIER, however, it should be mentioned that in our hands they produce the best 
correlation with real-time PCR data (in comparison with MAS5.0, gcRMA, and dChip 
algorithms). Because of this, it was chosen to use the RMA algorithm (Irizarry et al. 
2003) with log2 transformation for all pre-processing of expression microarray data in 
this thesis. 
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2.3 BIOBANKS 
The studies described herein are based on the Biobank of Karolinska Endarterectomies 
(BiKE) and the Advanced Study of Aortic Pathology (ASAP). It can hardly be 
understated how important these two biobanks have been to this thesis. A biobank is a 
collection of several biological samples together with clinical information about the 
samples. How many samples and how much information vary (Shalhoub et al. 2011). 
In the BiKE and ASAP databases, information is available on clinical records, 
biochemical measurements, ultrasound imaging, follow up, genotype profiling and 
expression profiling in several different tissues. All these measurements taken together 
provide one of the highest amounts of information per patient in any existing 
cardiovascular biobank study. The trade-off to this is that expansion of sample size 
becomes very costly. Both in monetary material-cost but also from the fact that each of 
these biopsies are taken during surgery at times when a multitude of other clinical 
priorities are in effect. 
The BiKE database consists of plaque samples removed during carotid endarterectomy 
on consecutive patients treated at the Karolinska Hospital (Figure 4). Carotid 
endarterectomy is indicated in cases of substantial narrowing of the carotid artery, as 
detected with duplex ultrasound. Typically, a patient presents with symptoms of 
transient ischemic attacks, stroke, or amaurosis fugax. Endarterectomy is also indicated 
in men with asymptomatic narrowing of the carotid artery. The efficacy of the surgery 
was established in the NASCET trial (Ferguson et al. 1999) and the ECST trial (ECST 
1998). The NASCET criteria were used for selection, and no further exclusion criteria 
were pre-defined. For some BiKE-investigations ad-hoc criteria (e.g. atrial fibrillation 
exclusion) have been applied subsequently, as described in relevant publications. Other 
biobanks of carotid endarterectomies have been described in (Hurks et al. 2009; 
Goncalves et al. 2010; Saksi et al. 2011). 
The ASAP database consists of biopsies taken during consecutive elective surgeries for 
aortic aneurysm and aortic valve repair. Inclusion criteria was age above 18 and aortic 
Figure 4. Ongoing carotid endarterectomy at the Karolinska Hospital. Photo 
provided by professor Jesper Swedenborg. 
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valve disease (aortic stenosis or regurgitation) or ascending aorta dilatation (aneurysm 
or ectasia). Exclusion criteria included coronary artery disease as defined by coronary 
angiogram. More clinical details can be found in (Jackson et al. 2011b). Patients were 
classified as having either BAV or TAV and as having either dilated or non-dilated 
thoracic aorta. The criteria for the latter were >45 mm (dilated) and < 40 mm (non-
dilated), respectively. These thresholds are based on clinical guidelines which indicate 
surgery at 40 mm dilation in BAV patients and 45 mm dilation TAV patients.  
Description of sample size of the biobanks is complicated by the fact that some 
measurements only have been performed in some of the samples. There are 489 BiKE 
individuals and 500 ASAP individuals, but this number is not very informative, 
because analysis effectively is performed only on the expression microarrays. This fact 
does leave open possibilities of validation in independent patients, however. Figure 5 
describes current sample composition in more detail. Note, however, that both biobanks 
are continuously being expanded and that sample sizes in earlier papers are somewhat 
less than indicated here.  
 
All BiKE 
individuals 
All ASAP 
individuals 
PBMC 
(n = 98) 
Plaque 
(n = 127) 
Aorta med. 
(n = 139) 
Aorta adv. 
(n = 133) 
97 30 1 
Mammary artery 
(n = 89) 
Transplant donor 
(n = 10) 
Transplant donor aorta 
(n = 13) 
10 
13 
29 58 
30 
36 
9 16 
28 
Liver and 
heart not 
shown 
 
 
 
Figure 5. Overview of expression microarray measurements in BiKE and ASAP, as 
of October 2011. For ASAP there are 309 individuals with at least one array and a 
total of 700 arrays. For BiKE there are 138 individuals with at least one array and a 
total of 235 arrays. Genotyping microarray measurements overlap with expression 
microarray measurements for all but 2 BiKE patients and all but 1 ASAP patient. In 
addition to the samples shown for ASAP, there are expression array measurements 
from 127 heart biopsies and 212 liver biopsies. A majority of these overlap with the 
vascular samples. 
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Both the BiKE and the ASAP biobanks are large collaborative efforts, and the papers in 
this thesis merely represents a small part of the output. For further reading on other 
aspects of both biobanks see Table 1 and Table 2. 
 
 Main finding Role of BiKE 
(Agardh et al. 2011) Finds FABP4 as the most 
differentially expressed 
transcript in unstable plaques 
Central role in unbiased 
identification of FABP4 
(Breland et al. 2010) MCP-4 levels are increased in 
patients with symptomatic 
carotid atherosclerosis 
In vivo plaque mRNA 
measurements 
supporting main data 
(C4D 2011) GWAS that identifies five 
new risk-SNPs for myocardial 
infarction 
Finding expression 
quantitative trait loci 
(eQTL) effects of novel 
GWAS risk-SNPs 
(Diez et al. 2010) Theoretical overview of 
network analysis methods 
Methodology 
exemplified using 
BiKE expression data 
(Folkersen et al. 2009b) Investigation of real-time 
PCR normalization methods 
Central role as source 
of gene expression 
measurement 
(Folkersen et al. 2009c) Paper II Essential 
(Folkersen et al. 2010) Paper III Essential 
(Gabrielsen et al. 2010) TBXAS1 is increased in 
murine atherosclerosis and 
correlates with macrophage 
markers 
Major role on 
macrophage marker 
correlation 
(Gertow et al. 2011) Investigation of leukotriene 
genes in plaque highlights 
ALOX15B  
Central role as source 
of all gene expression 
measurement 
(Malarstig et al. 2008) IRF5 is expressed in the 
atherosclerotic plaque and is 
affected by proximal SNPs 
Major role as source of 
eQTL measurements to 
match with association 
studies 
(Olofsson et al. 2009) Tnfsf4 expression was 
associated with increased 
atherosclerosis in mice. 
A role in human gene 
expression together 
with other major 
biobanks 
(Qiu et al. 2006) Leukotriene component 
LTA4H is correlated with 
time from last symptom in 
Major role as human in 
vivo validation of 
animal model data 
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plaque 
(Razuvaev et al. 2011) Investigation of a selected set 
of 317 known atherosclerosis 
genes  
Central role as source 
of all expression 
measurements on the 
gene set 
(Tran et al. 2007) HSPG2 is reduced in human 
atherosclerotic lesions 
Central role as the 
source of all 
immunostaining and 
gene expression 
material 
(Ueland et al. 2009) Broad mechanistic and 
clinical studies on DKK-1 
levels in atherosclerosis 
In vivo plaque mRNA 
measurements 
supporting main data 
(Wang et al. 2011) Expression of IGFs and IGF-
binding proteins in human 
carotid atherosclerosis 
Central role as the 
source of all gene 
expression material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Overview of all publications that uses data from BiKE. 
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 Main finding Role of ASAP 
(Bown et al. 2011a) GWAS that identifies one 
new risk-SNP for abdominal 
aortic aneurysm 
Finding eQTL effects 
of LRP1 gene. 
(C4D 2011) GWAS that identifies five 
new risk-SNPs for myocardial 
infarction 
Finding eQTL effects 
of proximal genes. 
(Folkersen et al. 2009c) Paper II Essential 
(Folkersen et al. 2010) Paper III Essential 
(Folkersen et al. 2011) Paper IV Essential 
(Gretarsdottir et al. 2010) GWAS that identifies one 
new risk-SNP for abdominal 
aortic aneurysm 
Finding eQTL effects 
of DAB2IP gene. 
(Jackson et al. 2011a) Investigations of MMP gene 
expression in TAA patients 
finds MMP14 and 19 to be 
differentially expressed 
Central role as source 
of MMP expression 
measurements 
(Jackson et al. 2011b) Studies on cusp morphology 
implying intrinsic 
mechanisms as source of 
BAV-related TAA 
Central role as source 
of all morphology 
measurements 
(Kurtovic et al. 2011) New method to investigate 
alternative splicing and 
identification of TGF-beta 
gene splice variants 
Central role as source 
of exon expression 
measurements 
(Paloschi et al. 2011) Known splice isoforms of 
fibronectin differs with with 
cuspidity of TAA patients 
Central role as source 
of fibronectin gene 
expression 
measurements 
(Strawbridge et al. 2011) GWAS that identifies nine 
new risk-SNPs for pro-insulin 
levels 
Expression level and 
eQTL effects of 
proximal genes. 
 
Table 2. Overview of all publications that uses data from ASAP. 
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2.4 STATISTICS 
All calculations in this thesis have been performed in the R/Bioconductor programming 
language (Gentleman et al. 2004; R Development Core Team 2011). Choice of 
statistical tests has been prioritized towards the simplest test-type that would suffice for 
the question at hand. In addition to a large number of Student’s T-tests and Pearson 
correlations, this includes a few more advanced concepts which will be described here. 
A feature of exclusively scripting all statistics is that all calculations are saved for later 
review – this is useful both in cases of auditing suspected errors and whenever previous 
methods are required in similar but not identical context. Altogether the calculations 
performed during the creation of this thesis consists of 168 846 lines of R-code, 
collected in 805 script-files. A web-interface connecting a graphical user interface to 
the most frequently used scripts is under development. This project can be found under 
the name of ExpressionWebExpress, at code.google.com.  
2.4.1 Additive linear models for eQTLs 
The analyses in Paper I, II, and III makes extensive use of additive linear models for 
detecting association between SNPs and gene expression levels. It is therefore 
important to thoroughly understand the mechanism of this test. In a more general sense, 
linear modelling or linear regression is a widely used method for describing any 
response variable as a function of several covariant variables. In the simplest case of 
two numerical variables, it will simply give the slope of the best fit of a regression line 
describing variable Y as a function of variable X. In the specific context of eQTL 
studies this is very often used as a so-called additive linear model, where the expression 
level of a gene is modelled as a function of genotype, where genotype is encoded 
numerically as e.g. 0 for AA, 1 for AG, and 2 for GG. When expression and 
Figure 6. Each dot shows a gene expression measurement in a patient with a given 
genotype from an arbitrary SNP, which can be either AA, AG or GG. In the example 
to the left there is a clear association between genotype and expression and the P-
value of a linear-additive model is much below 0.05. In the example to the right, 
there is no association and the P-value of a linear additive model is above 0.05. 
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numerically encoded genotype are used as input in a linear model function, an estimate 
of the slope and a P-value is obtained. The magnitude of this estimate can be 
interpreted as the per-allele effect of the genotype on the expression level. Because of 
the log2-scale expression data used, a value of 1 therefore equals a doubling of gene 
expression. As usual the P-value is the probability that the null hypothesis is true, 
where the null hypothesis in this case is when the genotype has no effect on the gene 
expression level. An example of both a significant association and a non-significant 
association is given in Figure 6. Alternatives to the additive linear model for eQTL 
studies, is the use of the Spearman rank correlation. This non-parametric statistic is 
preferred in non-normally distributed data sets, which is rarely the case in this thesis. 
2.4.2 Cox proportional hazards regression model 
The survival analysis in Paper V revolves around the use of the Cox proportional 
hazards model, or Cox-model. This model is essentially an extension of the linear 
model with time as the main covariate. However, the model has the important addition 
that data points either can be exact (“an event happened precisely at this time”) or 
boundaries (“no event happens before this time”, also known as censored points). An 
example of this is given in Figure 7, where four patients are recruited into a survival 
study. Patients 1 and 2 suffer from an adverse advent in the beginning of 2011. 
Although patient 1 has the event before patient 2, he still is registered as having a 
longer follow up time because he was recruited into the study at an earlier time. 
Patients 3 and 4 do not have any adverse events. Nonetheless we have to treat them 
differently in our calculations because patient 4 has been followed for a much shorter 
time, and could have suffered from an adverse event at some time in late 2010 after the 
end of his follow-up time. The particular reasons why patients 3 and 4 are not in the 
study anymore are not essential, as long it is not an event of the type under study. In the 
case of patient 3 for example the study simply reached its end-date. For patient 4 it 
could have been either a death due to unrelated factors (e.g. an automobile accident) or 
because of loss of follow-up, such as moving to another continent. 
 
Figure 7. Example of four patients in a survival study. 
Calendar time 
2012 2011 2010 2009 
1 
2 
3 
4 
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The purpose of the Cox-model is to estimate and quantify how likely it is that a clinical 
variable is associated with chance of event-free survival. This is extensively used in 
Paper V, where clinical variables with known effect on survival, such as age, gender 
and smoking are compared with new variables based on genetics and transcriptomics. 
In evaluating prognostic properties of any type it is common to provide receiver 
operating characteristic (ROC) curves. The ROC curve describes how capable a 
measurement is at correctly categorizing samples in two groups. The main advantage of 
a ROC curve is that it shows how capable the measurement is at all thresholds values. 
The measurement threshold where a sample is categorized as positive does therefore 
not have to be pre-specified.  
A plot of the ROC curve is necessary to fully interpret the range of all possible 
thresholds. However, a common derivate statistic to summarise the same information is 
to calculate the area under the curve (AUC). The AUC is connected to the probability 
that a true positive will have higher prediction score than a true negative. An AUC of 
0.5 therefore indicates that true positive or true negative samples are equally likely to 
have higher prediction scores, i.e. a useless prediction based on pure chance. An AUC 
of 1.0 on the other hand indicates that prediction scores will always be higher for true 
positive samples, i.e. a perfect prediction that is always correct. 
2.4.3 Multiple testing correction 
Throughout this thesis, multiple testing issues play a large role and it is therefore 
important with a careful explanation of the causes and consequences of multiple 
testing. A P-value indicates the probability that an observation, such as a change in 
gene expression, is not correct. By convention it is accepted that this probability has to 
be 5% or lower before a researcher can present anything as significant. However, 
because the 5% probability of non-difference exists at every single test, an example 
study with 20 Student’s T-tests performed on completely randomly generated numbers 
would have a 64% probability of having at least one P-value below 5% by pure chance. 
This is the reason for multiple testing correction. 
Several approaches exist to correct for multiple testing. The simplest is known as 
Bonferroni correction. In this method the P-values obtained are multiplied by the 
number of tests, and then required to be below 5%. A common criticism against the 
Bonferroni correction is that it is overly conservative with inflated false-negative rate. 
A handful of other multiple testing correction methods exist. The tests vary in the 
amount of correction, but they all lower the P-value threshold from the non-corrected 
5%-level to a value that is increasingly lower with the number of tests performed. One 
such test that is used in Paper III and IV is the false discovery rate (FDR). This test 
reports the proportion of false positives in a set of significant results, rather than the 
probability of the individual tests being false positive. Beneath the semantic difference, 
however, it is still a method to lower the P-value threshold in order to take multiple 
testing into account. 
Multiple testing issues are in fact so central to any data intensive analysis that it will be 
explained once more using simpler terminology. For average coins, heads-up and tails-
up happens half of the time. If we were to find a coin that landed heads up 9 out of 10 
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times, it would be special. This is essentially the same kind of special that we search for 
in genes and SNPs. However imagine that a special coin had been identified from a 
group of 99 other coins, all of which had been flipped 10 times each. Intuitively this 
makes the special coin less special. A single coin out of hundreds would probably just 
be found by chance. Theoretically it is in fact not special. The calculated probability 
that one coin will be heads 9 of 10 times is 1.07%. The calculated probability of this 
happening in at least one coin out of a hundred is 66%. 
2.4.4 Cross-validation 
Multiple testing is just one issue on a long list of biases and problems that can 
contribute to false positive results. For this reason it should be demanded that results 
are validated. The type and level of validation can vary. Doubts about measurement-
accuracy require technical validation, using independent methods. Doubts about 
general reliability of results require biological validation, using independent samples. 
More extraordinary claims require more extensive validations. A typical experimental 
setup, as for example used in GWAS, is to use a discovery cohort and a validation 
cohort. Because methods and techniques can differ between these cohorts, this can even 
have the advantage of overcoming many hidden biases. On the other hand the technical 
differences might cause perfectly true results to be rejected on false grounds, so it is 
advisable to change as few things as possible in each validation. 
Sometimes validation cohorts are not available. There can be several reasons for this, 
but ultimately it usually relates to time, costs and sample-restraints. If the cohort being 
studied is large this does not need to be a problem. Obviously one could just randomly 
split the total cohort into two halves and name one discovery and another validation. 
This would work, and would yield correctly validated results – albeit only with the 
power of half the samples.  
The split would also work if a larger fraction of the total cohort was reserved as 
discovery-cohort, and this would increase the power to detect correspondingly. The 
disadvantage is that with a smaller validation cohort the validation becomes less 
precise. Importantly, however, it does not become less accurate. The difference 
between precision and accuracy is important here. The more precise estimate will more 
often give the same value when repeated. The more accurate estimate will on average 
be closer to the correct value. Thus, if we imagine a very small validation-cohort of, 
say, two samples, we would have almost all the power and accuracy of the remaining 
total cohort, but our estimate would be extremely imprecise. It would not be advisable 
to rely on such imprecise estimates. 
Building on the above argument, cross-validation is introduced. In cross validation the 
data set is split as described above, the discovery calculation is performed, the 
validation calculation is performed, and then the entire process is repeated again – this 
time with a new and different split of the data sets. For each of these repetitions an 
estimate is recorded. This estimate has high accuracy, but low precision. All the part-
estimates taken together, however, will give a more precise and accurate estimate of the 
magnitude of the effect (Simon et al. 2003).  Cross-validation is an established part of 
prediction studies based on expression profiles in cancer, e.g. (Tibshirani et al. 2002; 
Borup et al. 2010). 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
The purpose of Paper I (Folkersen et al. 2009a) was to present a software package that 
could visualize expression microarray data at the most detailed level possible. The 
motivation for creating this software package was the incomplete annotation of the 
chromosome 9p21 region, which recently had come into focus as a major myocardial 
infarction risk locus and which would be the focus for Paper II. 
A standard analysis of Affymetrix expression arrays rely on the use of Affymetrix-
provided annotation files. Principally one file is needed for mapping between gene 
names and probe set ID-numbers and another is needed for mapping between probe set 
ID-number and the physical array location of each probes in the probe set. Practically, 
there are quite a few differences in the setup depending on the array-type. For example, 
to get from physical probe-location to gene name in the ST 1.0 class of arrays, four 
mapping files are required; the pgf-file, the clf-file, the mps-file and the transcript.csv 
file. More detail is provided in Figure 3 in the methods section. For the purposes of this 
paper, however, the important point is that the measured expression of a gene is 
understood to depend on the hybridization to a set of defined probes – but that this set 
definition is given by Affymetrix-provided annotation files. 
As described in the quality metrics section of methods, this setup works adequately for 
most cases of gene expression analysis. The expression of a gene with well-defined 
exon-boundaries and no transcript variants should theoretically be completely described 
by the hybridization-intensity of probes matching to its sequence. In this case, any 
measurement error can be attributed to unavoidable technical noise. In cases where the 
annotation is incomplete, however, the theoretical soundness fails. If for example, a 
poorly characterized gene is defined by 20 probes, but only 10 of these are actually in 
transcribed regions – then the measured expression value will be half of the true 
expression value. This is particularly a problem in genes with imprecise exon-
boundaries. 
The solution to this problem was to develop a software package that could extract the 
hybridization intensity and the nucleotide sequence of individual probes in any gene 
from any set of raw data files. This was combined with functions that allowed matching 
of extracted probe sequence with downloaded gene sequence and easy plotting of 
expression as function of gene-location. All these different data components were 
readily available in the raw data and downloadable annotation files, but even with 
knowledge of where to look it took time to find and match them all. With a software 
package, this time was reduced from hours of manual work to minutes of processing 
time, as well as a simplification of the amount of technical background required to 
understand. The software package was named GeneRegionScan. 
Fast and easy matching of individual probe sequence with gene sequence provided by 
the user can resolve the problem of incomplete annotation. If the Affymetrix-provided 
annotation is problematic, the user can easily provide new annotation in the form of 
simple gene sequences. This can be either sequence with the latest updated information 
or custom information based on results from ongoing studies. 
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With the help of the Bioinformatics Center at Kyoto the script was adapted to R-
package format and published in the Bioconductor repository. Since publication in 
august 2009, it has been downloaded a little more than 100 times per month – 
approximately equal to the median amount of downloads of all software packages in 
the Bioconductor repository. 
 
3.2 PAPER II 
The purpose of Paper II (Folkersen et al. 2009c) was to investigate the functional 
consequences of the chromosome 9 genetic variation that had been robustly associated 
with risk of cardiovascular disease. As already referred to in the introduction section, 
this variant was the first SNP to be associated with cardiovascular disease through the 
use of GWAS (Helgadottir et al. 2007; McPherson et al. 2007; Samani et al. 2007; The 
Wellcome Trust Case Control Consortium 2007). One common variation with larger 
effect size has subsequently been identified (Clarke et al. 2009), but the 9p21 risk allele 
is still today the most significant association between a SNP and cardiovascular disease 
(C4D 2011; Schunkert et al. 2011).  
The rs2891168 SNP investigated in Paper II was part of an LD block consisting of 14 
SNPs in high linkage disequilibrium with each other (Broadbent et al. 2007). Because 
of this, GWAS studies have often reported on the different SNPs in this region as 
equivalents. The SNPs in the haploblock were found to span a sparsely described gene, 
by the gene symbol of CDKN2BAS. A previous study from the field of cancer had 
linked the deletion of this gene to cancer in a French family and the gene was named 
Antisense Noncoding RNA in INK4/ARF Locus (ANRIL) (Pasmant et al. 2007). Based 
on this study, ANRIL was annotated as having a long 19-exon form and a short 13-
exon form. Work by our collaborators at the Oxford Wellcome Trust Centre for Human 
Genetics showed that the alternative splicing of ANRIL was more complicated than 
what was shown in the annotation data base (Figure 8, with UCSC genome browser 
data) and previous sequencing work (Pasmant et al. 2007). The annotated short and 
long isoforms could not be readily detected, but 8 novel exon-combinations of the 
ANRIL gene were found based on exon 1, 14 and 20 PCR primer amplification 
followed by capillary sequencing. 
At the time of publication of Paper II, two other functional real-time PCR based studies 
of the 9p21 risk locus had recently been published: one study showed that the 9p21 risk 
allele was associated with decreased expression of the neighbouring genes CDKN2A, 
CDKN2B and ANRIL in peripheral blood T-cells from 170 healthy individuals, 
measured at an unreported exonic location (Liu et al. 2009). Another study showed an 
association between the 9p21 risk allele and increased expression levels of the “short” 
transcript of ANRIL in whole blood cells from 124 healthy individuals (Jarinova et al. 
2009). The same study reported that the “long” transcript isoform of ANRIL had 
decreased expression with the risk allele. 
With at least 10 different transcript isoforms of ANRIL detected, it was clear that a 
single real-time PCR based measurement point on the gene was insufficient. It could 
even be speculated that there was no inconsistency between the studies by Liu and 
Jarinova, but that they merely were measuring different splice variants. We therefore 
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turned to expression microarrays and the newly developed GeneRegionScan package 
from Paper I, which had in fact been developed towards this use. 
The data sets at our disposal at the time was the BiKE database of carotid plaque 
samples, the ASAP database in an early version that consisted of a subset of the aorta 
media and mammary artery media samples, and two publically available expression 
microarray databases from Gene Expression omnibus (Edgar et al. 2002). The BiKE 
and ASAP databases at that time had genotype specific PCR-genotyping performed for 
the rs2891168 SNP. The two publically available data sources were the CEU HapMap 
dataset (HapMap 2003), which provided genotype data, and an expression microarray 
database (Kwan et al. 2008; Zhang et al. 2008), which provided gene expression from 
lymphoblastoid cell lines from the same HapMap individuals. 
Consequently, the hypothesis being tested was if any particular exon-region of ANRIL 
or any other proximal gene was associated with the 9p21 risk allele. The somewhat 
disappointing result of testing this hypothesis was that no clear region of association 
could be observed. In the publication of these findings our aim was to highlight the 
inconsistencies involved in reporting gene expression measured in arbitrary exons of a 
gene with known alternative splicing. 
Shortly after the release of Paper II, it was published that ANRIL had increased 
expression with the 9p21 risk allele in peripheral blood mononuclear cells from 1098 
healthy individuals (Holdt et al. 2010) and that ANRIL had decreased expression with 
the 9p21 risk allele in the leukocytes of 487 healthy individuals (Cunnington et al. 
2010). In total that brought the number of studies of ANRIL expression and 9p21 risk 
genotype up to 5, with serious disagreements in observed direction (Table 3). This 
disagreement has not been clearly resolved, but a number of speculative reasons should 
be mentioned. Tissue type could be one possible reason. All effects have been observed 
Figure 8. Overview of the 9p21 region around ANRIL. Gene annotation and 
alignment to other animal species downloaded from UCSC genome browser (Kent et 
al. 2002). Note that the UCSC genome browser only shows a few of the ANRIL 
transcript variants that are known today. Red box indicates the span of the risk 
haploblock (Broadbent et al. 2007) and the thin black vertical line within indicates 
the position of rs2891168. 
CDKN2A 
ANRIL 
ANRIL 
ANRIL 
CDKN2B 
CDKN2B 
ANRIL 
Chr 9 – MB:  21.99 22.00 22.01 22.02 22.03 22.04 22.05 22.06 22.07 22.08 22.09 22.10 22.11 22.12 
MTAP 
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in circulating cells and it is possible that this effect is specific to the immune system. 
This cannot be a full explanation since inconsistent directions are reported for the same 
cell types. Secondly, alternative splicing could be another reason. As asserted in Paper 
II, variations in exonic location of measurement points could result in different 
transcript isoforms being measured. Thirdly, with a high-profile finding like the 9p21 
risk locus, there is an increased risk of the so-called winner’s curse – which is simply to 
say that if many different research groups initiated investigations and only the groups 
with significant results reported on them, there would be a large risk of selecting for 
false positive findings. Finally, a very possible reason is that half the groups have 
mistaken the risk locus for the non-risk locus. Unfortunately, this is not entirely 
unlikely, and would underscore how ambiguous the technical identification of strands is 
in major genotyping platforms and databases. An allele from any human SNP can 
currently be reported in at least three strand definitions (dbSNPs forward/reverse, 
reference genome positive/negative, Illumina TOP/BOT). Various genotyping methods 
uses various definitions. To safeguard against this, a check of allele frequencies is 
usually performed during the analysis. In paper III, for example, all indications of 
direction are accompanied by an indication of frequency. However, because the 9p21 
locus has a frequency of close to 50%, a flip of strand would never be revealed to 
researchers. 
 Tissue Sample size ANRIL direction with risk 
locus 
(Liu et al. 2009) Peripheral blood 
T-cells 
170 Decrease 
(Jarinova et al. 
2009) 
Whole blood cells 124 Increase and decrease, 
depending on transcript 
(Folkersen et al. 
2009c) 
Various, vessel 5 x ~100 No change 
(Holdt et al. 2010) Peripheral blood 
mononuclear cells 
1098 Increase 
(Cunnington et al. 
2010) 
Leukocytes 487 Decrease 
 
Naturally other methods have been brought to bear in the functional investigation of the 
9p21 SNPs. Long range interaction studies have implicated STAT1 as a downstream 
target (Harismendy et al. 2011). STAT1 is involved in the response to interferons, 
providing a putative link to the immune system and a support of circulating cells as 
study material for the 9p21 locus. Yet other methods have shown that ANRIL is 
important in epigenetic silencing (Yap et al. 2010) and some groups have even sought 
to investigate knock-out mouse models of the 9p21 region (Visel et al. 2010), even 
Table 3. Overview of 2009-2010 studies of ANRIL expression and 9p21 risk 
genotype. 
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though the genetic similarity in this region is so low that it is unlikely that rodents will 
be very informative (Figure 8). 
Finally, the question of alternative splicing was recently revisited in a very interesting 
study of ANRIL using RNA sequencing and rapid amplification of cDNA ends (Burd 
et al. 2010).  Several new transcript variants were discovered, association with 9p21 
risk genotype was found for some of them, and as, perhaps the most fascinating part, it 
was shown that several of the transcript variants were round rather than linear. 
In a broader perspective, the interest in the function of the 9p21 risk genotype 
mechanism is more than just of academic interest to molecular biology. One stated 
potential of the GWAS was to provide better medical diagnostics methods. However, 
the variation in common disease patterns explained by GWAS risk SNPs is now known 
to be a relative small. A compelling alternative use of the GWAS is therefore to provide 
knowledge of new pathways and putative drug targets. Such a target could for example 
be the mechanism that dictates that an individual with a 9p21 risk-allele has a higher 
risk of early myocardial infarction than an individual without. However, in spite of 
much research, it is fair to say that we still do not know this mechanism today. 
3.3 PAPER III 
The purpose of Paper III (Folkersen et al. 2010) was to investigate whether any 
established risk SNPs were associated to the expression levels of nearby genes. Inspired 
by the inquiry into the 9p21-risk allele mechanism and its effect on gene expression, we 
hypothesised that a similar investigation of all other known risk SNPs would reveal 
more clear cases of eQTLs. At the time of publication, there were 17 SNPs with 
established association to myocardial infarction (Samani et al. 2007; Erdmann et al. 
2009; Kathiresan et al. 2009b). In addition we made a selection of SNPs relevant to 
risk-factors, intermediate traits and other cardiovascular diseases. These included 
lipoproteins, triglyceride, hypertension, atherosclerosis, abdominal-aortic aneurysm and 
waist circumference, and gave a total of 168 established risk SNPs.  
The method of Paper III was straightforward: for each of these 168 risk SNPs we 
identified all genes within 200 kb distance. For each of these genes we compared the 
expression levels with the genotype of the SNP in question. This was done in each of 
the tissues available in the BiKE and ASAP biobanks: liver, mammary artery, aorta 
media, aorta adventitia and carotid plaque. If the association between gene expression 
and genotype was significant at P < 0.005, it was reported as a risk-SNP eQTL. 
Using this method we found 47 SNPs that had at least one proximal, significantly 
associated gene, in at least one of the investigated tissue types. By far the most likely 
interpretation of this finding is that the risk associated with the SNP is mediated 
through the gene associated with the SNP. As noted in the discussion, one reason of the 
popularity of the GWAS is their delineation of cause and effect.  The strength of the 
eQTL approach is that it extends this cause and effect delineation to actual genes. One 
can assume that the SNP must be the cause of the altered disease risk, and that the SNP 
must be the cause of the altered gene expression level – if this assumption is true, the 
altered gene expression level should be the cause of the altered disease risk. And the 
assumption can indeed be confidently made – a disease or a gene product that affects 
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the sequence of the DNA of an entire organism is highly improbable. The eQTL 
method therefore allows the extension of GWAS results from risk-SNPs to risk-genes. 
In addition to the presentation of these 47 novel gene targets, the paper contains three 
considerations of more conceptual nature. The first point is that risk-SNPs are more 
likely to have eQTL effects than non-risk SNPs. This was shown by comparing the 168 
known risk-SNPs with random samplings of non-risk SNPs, each set having similar 
size and frequency. In 10 samplings and complete re-calculations, there was found no 
SNP set with stronger eQTL associations than the 168 known risk-SNPs. We therefore 
made the conclusion that risk-SNPs mechanism is often likely to be mediated through 
gene expression change. 
Secondly, we observed that the SNP was not always found directly in or next to the 
associated gene. Of the 47 significant eQTLs, 22 were associated with genes at 
distances of more than 35 kb. Moreover, the most proximal gene only occasionally 
showed the most significant eQTL effect. This might seem like a trivial observation. 
However, it goes firmly against the GWAS convention of labelling risk-SNPs with the 
name of the closest gene or gene-clusters. Based on these results, we conclude that the 
labelling risk-SNPs by the closest gene-name will often be misleading. Additionally it 
is worth noting, that we only could conclude on effects within the ±200 kb window. 
Even more distal eQTL effects would not have been detected. This distance limit was 
required to control the multiple testing issues. It was based on reports that a majority of 
general eQTL effects were observed at this distance (Dimas et al. 2009) as well as on 
the fact that none of these particular risk-SNPs were found in haploblocks of larger 
size. 
Thirdly, we found that the risk-SNP phenotype was often determining the tissue type in 
which the eQTL was observed. For example the risk-SNPs originally found to be 
associated with lipid-levels often showed association with gene expression only in 
liver. Conversely, there were a higher proportion of vessel-wall eQTL effects from risk-
SNPs that were originally determined to be associated with myocardial infarction 
independently of lipid levels. This specificity was even observed when gene expression 
level where similar or higher in non-eQTL tissues. This observation has implications 
towards the choice of sample material in future eQTL studies. Because of sampling 
accessibility, most published eQTL studies are based on samples from circulating 
blood. This is advantageous when studying risk-SNPs associated with phenotypes of 
the cells of the circulating blood. When studying risk-SNPs associated with other 
diseases it is recommendable to study eQTLs in tissue types linked to these diseases.  
Taken together, the findings in Paper III illustrate one way to pursue GWAS results 
further towards clinical application. As with the specific 9p21 functional analysis, it 
should be beneficial towards the identification of putative drug targets. It has already 
been beneficial for the GWAS papers in which we have collaborated based on this 
method (Gretarsdottir et al. 2010; Bown et al. 2011a; C4D 2011; Strawbridge et al. 
2011). 
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3.4 PAPER IV 
The purpose of Paper IV (Folkersen et al. 2011) was to analyze the overall gene 
expression profile of the patients in the ASAP database. The ASAP database was 
designed with the intention of answering a specific clinical question about thoracic 
aortic aneurysm (TAA). As described in the introduction section, TAA is a common 
complication in patients with a bicuspid aortic valve (BAV). It is today not known why 
TAA consistently occurs at younger age and with a higher frequency in BAV patients 
than in patients with a tricuspid aortic valve (TAV). The purpose of Paper IV was to 
investigate this increased TAA incidence in BAV patients. 
The fundamental analytical approach of the study was to ask what gene expression 
changes was observed when comparing the dilated aorta with the non-dilated aorta. 
This question was asked both for the TAV and the BAV patients. Because these two 
patient groups both end up with aortic dilation, we hypothesised that observed 
expression changes that are common to the two groups more likely would be connected 
to the final common stages of dilation, whereas the observed expression changes 
unique to either group would be connected to earlier steps in the pathophysiology. 
When compared to the eQTL-methods described in Paper II and III, this approach 
certainly has less capacity to determine causality. However, the setup of the question is 
still an attempt towards delineating cause and effect. Doing this is an advance in 
comparison to other earlier expression microarray studies which simply reports 
differentially expressed genes as targets, notwithstanding that they could just as well be 
up-regulation of repair responses. The obvious strength of the Paper IV over the 
genetics-methods of Paper II and III is of course that there is more to pathophysiology 
than genetics.  
After establishing the main analytical approach, we were faced with a number of 
statistical choices. Many different statistical methods have been developed for the 
analysis of expression microarrays, and many arguments have been made as to why any 
given test is superior. The one advantage of the Student’s T-test is that it is universally 
recognised and understood. In a translational study that fact is not trivial. The second 
method we based our studies on, was gene set enrichment analysis (GSEA) (Luo et al. 
2009). Although less widespread, this test is attractive for its simple premise: in any 
defined group of genes, one asks if the genes are more differentially expressed than 
would have been expected by chance. The definition of gene groups is done separately 
from the analysis, but is usually taken as those defined by the Gene Ontology, which is 
a bioinformatics initiative aimed at categorizing all genes (Ashburner et al. 2000). Thus 
an output from a GSEA might report that in a given gene group, e.g. “vasodilation-
related genes”, there are many more differentially expressed genes than would have 
been expected for a similarly sized random group of genes. With these two tests, the 
Student’s T-test and the GSEA, we set out to compare aortic dilation in BAV and TAV 
patients. 
The first major observation was that the difference between the BAV and the TAV 
patients. Of the genes found to be differentially expressed with dilation, only few 
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(<4%) were differentially expressed in both BAV and TAV patients. This underscores 
a point that has only recently been appreciated, namely that these two patient groups 
exhibit vastly different molecular profiles (Siu et al. 2010). In contrast to this, we 
observed very little difference when comparing the non-dilated TAV with the non-
dilated BAV samples. This observation has impact on the open debate on the role of 
BAV-dependent hemodynamic changes, because similar pre-dilation profiles in both 
patient groups corresponds poorly with life-long flow-alteration as an explanation of 
increased TAA in BAV patients. Lists of individual genes that were differentially 
expressed in BAV, TAV or both are included as supplementary materials of the paper.  
The second major observation was from the GSEA, which showed that the cell 
adhesion and extracellular region genes had a much larger proportion of differentially 
expressed genes than expected by chance. This was true both in the BAV and TAV 
patients. Because aorta dilation is known as a disease that involves the degradation of 
structural proteins, this finding was not surprising. The other significant finding from 
GSEA, however, was that immune response genes were highly differentially expressed 
between BAV and TAV patients. The pattern of this regulation was better visualized 
using plots of the individual genes, such as figures 4 and 5 of Paper IV. Here it was 
seen that the observed GSEA scores were a result of a general up-regulation of the 
immune response in dilated aorta media from TAV patients, but not in BAV patients. 
This finding is clearly novel, and satisfies our initial hypothesis on differences and 
similarities between the BAV and TAV patients (Figure 9). In other words, we consider 
this to indicate that the immune response is involved at an earlier point in the aorta 
dilation pathogenesis. We consider this TAV-specific observation to be an important 
difference between BAV and TAV patients. 
Thoracic 
aorta 
aneurysm 
Inflammation 
genes 
BAV 
Extracellular 
matrix 
genes 
TAV 
 
Figure 9. Common and unique pathways activated in TAA pathogenesis suggest a 
causal order of events. In this conceptual framework several other established facts 
have been omitted for the sake of clarity. Examples are the monogenic forms acting 
through TGF-β (Loeys‐Dietz, Marfan) and COL3A1 (Ehlers‐Danlos), which 
illustrate other “starting-points” of disease that could be included here. 
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We observed no BAV-specific trends from the GSEA methodology. However, several 
individual genes were specifically up-regulated only in the dilated aorta of BAV-
patients, and these do satisfy our initial hypothesis. It is of interest to note some of these 
(PLXNA1, EP400 and BAT2) have previously been discussed in connection with BAV 
and TAA (Majumdar et al. 2007; Wooten et al. 2010). In addition, the TGF-beta 
binding proteins LTBP3 and LTBP4 were highly specific for dilation in BAV patients 
only. TGF-beta has previously been noted for its association to aortic dilation (Loeys et 
al. 2006; Paloschi et al. 2011). In the scope of this paper, however, we did not perform 
any further experimental analysis on any of these genes. In addition, it is of interest that 
one of the individually significant differentially expressed genes is the LRP1 gene, 
which recently was identified in a GWAS for abdominal aortic aneurysm (Bown et al. 
2011b). 
Further work on this project is expected to revolve around these gene targets. Because 
of the recent publication of this paper, however, these projects are only in early 
planning stages.  
3.5 PAPER V 
The purpose of Paper V, which is not yet a published article, is to investigate what 
genomics and transcriptomics can reveal about the medical future of patients with 
established atherosclerosis. Predicting the medical future of individuals is inherent to 
any clinical setting in which a prognosis is given. In cardiovascular disease, guidelines 
typically include consideration of age, gender, smoking, cholesterol, diabetes, e.g. 
(Roques et al. 2003). Several other emerging biomarkers have been suggested and 
shown to have predictive properties, e.g. (Hellings et al. 2010; Peeters et al. 2010). In 
Paper V we ask if an omics-based approach to the question can be advantageous. 
Genomics-based approaches to prediction are the essence of the GWAS as already 
described. To our knowledge, there have not been any GWAS investigating the risk of 
ischemic events in patients with established atherosclerosis. However, because of the 
observation that risk-SNPs can be associated with several related phenotypes 
(Helgadottir et al. 2008), an inviting hypothesis is that risk SNPs for myocardial 
infarction will have predictive value in similar settings, such as in our patient cohort. 
This has for example been shown for the 9p21 myocardial infarction risk-SNP in 
patients undergoing coronary artery bypass surgery (Muehlschlegel et al. 2010). We 
therefore based the genomics-part of our prediction study on 25 SNPs with firmly 
established association to myocardial infarction (Kathiresan et al. 2009b; C4D 2011; 
Schunkert et al. 2011). 
The transcriptomics-based part could not benefit from already established risk genes, as 
no such studies had been performed. The closest such thing was a study of myocardial 
biopsies, which found 46 genes that were differentially expressed between patients with 
less than 2 year survival and patients with more than 5 year survival (Heidecker et al. 
2008). We therefore decided to pursue a de novo discovery of genes with predictive 
properties.  This was done both in the set of 126 carotid plaques and in the overlapping 
set of 98 peripheral blood mononuclear cell samples (PBMC), for which we had 
expression microarray data available. To obtain a realistic estimate of the predictive 
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properties, this was done using a leave-one-out cross-validation setup as previously 
recommended (Simon et al. 2003). 
Taken together, this provided us with risk scores based on the genome of the patients, 
the transcriptome of the PBMC, and the transcriptome of plaque tissues. For each of 
these the prognostic strength was calculated using a Cox regression model. The gene 
expression risk scores from carotid plaque had the best predictive power, at an AUC of 
0.72. Gene expression risk scores based on PBMC and scores from risk-SNP genotype 
had more moderate scores of AUC 0.59 and 0.55, respectively. We then compared 
these scores with classical risk scores. Classical risk scores were here defined as age, 
gender, LDL and smoking status, but other combinations of established risk factors 
were attempted with similar results. The combination of the classical risk scores, with 
the new transcriptomic and genomic risk scores improved the classical risk score from 
AUC 0.66 to AUC 0.79. Recall that an AUC of 0.5 corresponds to prediction by pure 
chance whereas 1.0 corresponds to flawless prediction. So this improvement is 
respectable. 
As an illustration of the prognostic power of these results we give an example of a test 
based on a set threshold for event prediction. If this threshold is set where it will 
identify 77% of the patients with future ischemic events, then the number of false 
positives will be 35% of the remaining patients. However, if gene expression profiling 
is not performed only 58% of the patients with ischemic events will be detected at the 
same false positive rate. This can also be stated as a need for testing 6 patients, for 
every extra correct prediction made with gene expression profiling. We believe that 
these findings may pave the way for better identification and treatment of patients with 
increased cardiovascular risk. 
One limitation of the study was the necessity of the leave-one-out cross-validation. 
Optimally results should be validated in an independent cohort. A suitable validation 
cohort would be a large biobank of carotid plaque samples having both global 
expression profiling data and clinical follow up information (preferably with a similar 
time-period and expression profiling method). At the moment, however such studies 
are left for future collaborations. 
In addition, it is important to note the choice of focus. Paper V is focused on the 
magnitude of improvement of prediction methods using high-throughput methods. We 
expect these findings to have impact in their own right, but there is another aspect that 
consequently is not in focus: the specific genes which contain the predictive properties. 
A main reason for this choice of focus is that we found that no genes were predictive 
after multiple testing correction. Nonetheless, the data contain several genes which 
have very significant levels of prediction. Without further validation it is not advisable 
to proceed with these. However, when that has been resolved it could conceivably 
overcome several other limitations. 
First of all the current sample analysis necessarily restricts the method to patients 
undergoing carotid endarterectomy. If individual predictive genes could be identified it 
could provide opportunities for much less invasive measurements of the products of 
these genes. Positron emission tomography imaging techniques have been developed 
towards the goal of detecting plaque properties, namely inflammation measured as the 
degree of fluorodeoxyglucose uptake (Tawakol et al. 2006; Pedersen et al. 2011). 
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Similarly one could speculate that imaging techniques directed towards a biomarker in 
the carotid plaque could be informative (Gustafsson et al. 2006). Of course a whole 
host of technical issues must be overcome for this to be possible. 
Secondly it is of course of interest to understand the mechanical basis of why the 
identified genes are predictive. Ultimately, a goal could be to provide drug targets as 
well as diagnostics tools. However, in such speculations it is extremely important to 
keep in mind that this prediction from expression levels is not better suited to establish 
cause and effect than any other comparative expression studies. The gene that is clearly 
increased in patients at increased risk of future ischemic attack, might just as well 
represent an essential healing function. The scope of this study is therefore solely 
diagnostic. 
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4 CONCLUSIONS 
The overarching purpose of this thesis was to investigate the expression of human 
genes and how they relate to cardiovascular disease. With this, it was hoped that a 
contribution could be made to the larger goal of improved treatment of cardiovascular 
disease. It is probably impossible to quantify how much improvement was in fact 
contributed, if anything at all. However, that can be argued with most basic research 
and it is nonetheless basic research that drives the discoveries that ultimately improve 
treatment. We therefore focus on the immediate basic research objectives that were 
accomplished: 
 We provided the first study of the transcript isoforms of the genes in the 9p21 
cardiovascular risk SNP region. 
 We identified 47 additional novel target genes using the eQTL methods on other 
risk SNPs. Additionally we contributed to a concept of systematically checking 
newly discovered GWAS results for eQTL effects, in order to move from target-
SNPs to target-genes. 
 We provided the first analysis of the gene expression differences between aorta 
dilation of BAV and TAV patients. This highlighted a possible fundamental 
difference in pathophysiology of these two forms of aortic aneurysm. 
 We showed as proof-of-principle that gene expression signatures from carotid 
plaque samples are able to measurably improve prediction of future myocardial 
infarctions and ischemic strokes. 
The underlying theme throughout the thesis has been that biobanks with human 
samples are crucial in answering fundamental medical questions. The overall 
conclusion therefore is that biobanks are important in translational research, and that 
future medical research to an even higher degree would benefit from investment in 
biobanks. 
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